16:28 EST Sangamo (SGMO) down 31% at $1.61 after Pfizer decision to terminate collaboration
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMO:
- Sangamo to regain rights to giroctocogene fitelparvovec from Pfizer
- Sangamo to receive $20M from Astellas Pharma in capsid license agreement
- Biotech Alert: Searches spiking for these stocks today
- Sangamo upgraded to Buy from Hold at Truist
- Sangamo Biosciences’ Legal Victory and Hemophilia Trial Success